FindTrial
Sign In

MANAGEMENT OF PRIMARY AND SECUNDARY PERITONEAL CARCINOMATOSIS FROM COLO-RECTAL CANCER, RECURRENT OVARIAN CANCER AND ABDOMINAL SARCOMATOSIS BY CYTOREDUCTIVE SURGERY PLUS HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY - ND

MANAGEMENT OF PRIMARY AND SECUNDARY PERITONEAL CARCINOMATOSIS FROM COLO-RECTAL CANCER, RECURRENT OVARIAN CANCER AND ABDOMINAL SARCOMATOSIS BY CYTOREDUCTIVE SURGERY PLUS HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY - ND

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2009-017437-22-IT
Enrollment
Unknown
Registered
2010-01-28
Start date
2010-02-24
Completion date
Unknown
Last updated
2014-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peritoneal carcinomatosis MedDRA version: 9.1 Level: LLT Classification code 10061344

Interventions

Trade Name: CISPLATINO TEVA*EV 50MG 100ML Pharmaceutical Form: Solvent for parenteral use INN or Proposed INN: Cisplatin Concentration unit: mg/m2 milligram(s)/square meter Concentration type: equal C

Sponsors

AZIENDA OSPEDALIERA DI PERUGIA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with peritoneal carcinomatosis from: -advanced ovarian cancer -colo-rectal cancer -small bowel cancer -gastric cancer -pseudomyxoma peritonei -peritoneal mesothelioma and other rare primary peritoneal cancer -recurrent abdominal and retroperitoneal sarcomatosis -positivity of peritoneal cytology -age >18 = 70 -no evidence of extra-abdominal disease -no intestinal obstruction -no evidence of renal, cardio-pulmunary, metabolic and liver failure -no previous abdominal radiotherapy Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: -tumor mass greater than 1 cm after debulking -colo-rectal cancer: PCI > 22 -creatinine clearance < 60 ml/ min

Design outcomes

Primary

MeasureTime frame
Main Objective: -Progression free survival (PFS);Secondary Objective: Toxicity and surgical complication;Primary end point(s): Overal survaival—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026